Literature DB >> 12499184

Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones.

Bhaskar R Shenai1, Belinda J Lee, Alejandro Alvarez-Hernandez, Pek Y Chong, Cory D Emal, R Jeffrey Neitz, William R Roush, Philip J Rosenthal.   

Abstract

The Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3 appear to be required for hemoglobin hydrolysis by intraerythrocytic malaria parasites. Previous studies showed that peptidyl vinyl sulfone inhibitors of falcipain-2 blocked the development of P. falciparum in culture and exerted antimalarial effects in vivo. We now report the structure-activity relationships for inhibition of falcipain-2, falcipain-3, and parasite development by 39 new vinyl sulfone, vinyl sulfonate ester, and vinyl sulfonamide cysteine protease inhibitors. Levels of inhibition of falcipain-2 and falcipain-3 were generally similar, and many potent compounds were identified. Optimal antimalarial compounds, which inhibited P. falciparum development at low nanomolar concentrations, were phenyl vinyl sulfones, vinyl sulfonate esters, and vinyl sulfonamides with P(2) leucine moieties. Our results identify independent structural correlates of falcipain inhibition and antiparasitic activity and suggest that peptidyl vinyl sulfones have promise as antimalarial agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499184      PMCID: PMC149004          DOI: 10.1128/AAC.47.1.154-160.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  Hemoglobin metabolism in the malaria parasite Plasmodium falciparum.

Authors:  S E Francis; D J Sullivan; D E Goldberg
Journal:  Annu Rev Microbiol       Date:  1997       Impact factor: 15.500

2.  Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

Authors:  D J Kempf; H L Sham; K C Marsh; C A Flentge; D Betebenner; B E Green; E McDonald; S Vasavanonda; A Saldivar; N E Wideburg; W M Kati; L Ruiz; C Zhao; L Fino; J Patterson; A Molla; J J Plattner; D W Norbeck
Journal:  J Med Chem       Date:  1998-02-12       Impact factor: 7.446

3.  Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.

Authors:  D M Feng; S J Gardell; S D Lewis; M G Bock; Z Chen; R M Freidinger; A M Naylor-Olsen; H G Ramjit; R Woltmann; E P Baskin; J J Lynch; R Lucas; J A Shafer; K B Dancheck; I W Chen; S S Mao; J A Krueger; T R Hare; A M Mulichak; J P Vacca
Journal:  J Med Chem       Date:  1997-11-07       Impact factor: 7.446

4.  Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors.

Authors:  P J Rosenthal; J E Olson; G K Lee; J T Palmer; J L Klaus; D Rasnick
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

5.  An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.

Authors:  A B Smith; R Hirschmann; A Pasternak; W Yao; P A Sprengeler; M K Holloway; L C Kuo; Z Chen; P L Darke; W A Schleif
Journal:  J Med Chem       Date:  1997-08-01       Impact factor: 7.446

6.  Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain I.

Authors:  S Chatterjee; M A Ator; D Bozyczko-Coyne; K Josef; G Wells; R Tripathy; M Iqbal; R Bihovsky; S E Senadhi; S Mallya; T M O'Kane; B A McKenna; R Siman; J P Mallamo
Journal:  J Med Chem       Date:  1997-11-07       Impact factor: 7.446

7.  Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.

Authors:  C A Veale; P R Bernstein; C M Bohnert; F J Brown; C Bryant; J R Damewood; R Earley; S W Feeney; P D Edwards; B Gomes; J M Hulsizer; B J Kosmider; R D Krell; G Moore; T W Salcedo; A Shaw; D S Silberstein; G B Steelman; M Stein; A Strimpler; R M Thomas; E P Vacek; J C Williams; D J Wolanin; S Woolson
Journal:  J Med Chem       Date:  1997-09-26       Impact factor: 7.446

8.  New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.

Authors:  G Bold; A Fässler; H G Capraro; R Cozens; T Klimkait; J Lazdins; J Mestan; B Poncioni; J Rösel; D Stover; M Tintelnot-Blomley; F Acemoglu; W Beck; E Boss; M Eschbach; T Hürlimann; E Masso; S Roussel; K Ucci-Stoll; D Wyss; M Lang
Journal:  J Med Chem       Date:  1998-08-27       Impact factor: 7.446

9.  Synchronization of Plasmodium falciparum erythrocytic stages in culture.

Authors:  C Lambros; J P Vanderberg
Journal:  J Parasitol       Date:  1979-06       Impact factor: 1.276

10.  Determination of the rate constant of enzyme modification by measuring the substrate reaction in the presence of the modifier.

Authors:  W X Tian; C L Tsou
Journal:  Biochemistry       Date:  1982-03-02       Impact factor: 3.162

View more
  33 in total

1.  Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites.

Authors:  Puran S Sijwali; Kentaro Kato; Karl B Seydel; Jiri Gut; Julie Lehman; Michael Klemba; Daniel E Goldberg; Louis H Miller; Philip J Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-27       Impact factor: 11.205

2.  The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif.

Authors:  Kailash C Pandey; Stephanie X Wang; Puran S Sijwali; Anthony L Lau; James H McKerrow; Philip J Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-17       Impact factor: 11.205

3.  Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery.

Authors:  Manoj K Ramjee; Nicholas S Flinn; Tracy P Pemberton; Martin Quibell; Yikang Wang; John P Watts
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

4.  Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease.

Authors:  Stephanie X Wang; Kailash C Pandey; John R Somoza; Puran S Sijwali; Tanja Kortemme; Linda S Brinen; Robert J Fletterick; Philip J Rosenthal; James H McKerrow
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

5.  Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.

Authors:  S Eksi; B Czesny; G-J van Gemert; R W Sauerwein; W Eling; K C Williamson
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

6.  Falcipain-1, a Plasmodium falciparum cysteine protease with vaccine potential.

Authors:  Amit Kumar; Krishan Kumar; Reshma Korde; Sunil Kumar Puri; Pawan Malhotra; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2007-01-22       Impact factor: 3.441

7.  Synthesis of macrocyclic trypanosomal cysteine protease inhibitors.

Authors:  Yen Ting Chen; Ricardo Lira; Elizabeth Hansell; James H McKerrow; William R Roush
Journal:  Bioorg Med Chem Lett       Date:  2008-06-10       Impact factor: 2.823

8.  Identification of cysteine protease inhibitors as new drug leads against Naegleria fowleri.

Authors:  Ingrid Zyserman; Deboprosad Mondal; Francisco Sarabia; James H McKerrow; William R Roush; Anjan Debnath
Journal:  Exp Parasitol       Date:  2018-03-15       Impact factor: 2.011

9.  Antimalarial activity of thiosemicarbazones and purine derived nitriles.

Authors:  Jeremy P Mallari; Wendyam A Guiguemde; R Kiplin Guy
Journal:  Bioorg Med Chem Lett       Date:  2009-05-05       Impact factor: 2.823

10.  Chemical genetics of Plasmodium falciparum.

Authors:  W Armand Guiguemde; Anang A Shelat; David Bouck; Sandra Duffy; Gregory J Crowther; Paul H Davis; David C Smithson; Michele Connelly; Julie Clark; Fangyi Zhu; María B Jiménez-Díaz; María S Martinez; Emily B Wilson; Abhai K Tripathi; Jiri Gut; Elizabeth R Sharlow; Ian Bathurst; Farah El Mazouni; Joseph W Fowble; Isaac Forquer; Paula L McGinley; Steve Castro; Iñigo Angulo-Barturen; Santiago Ferrer; Philip J Rosenthal; Joseph L Derisi; David J Sullivan; John S Lazo; David S Roos; Michael K Riscoe; Margaret A Phillips; Pradipsinh K Rathod; Wesley C Van Voorhis; Vicky M Avery; R Kiplin Guy
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.